Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers have discovered a way to potentially combat chemotherapy-resistant breast cancer, according to a study published in the journal Chemical Science.
Breast Cancer Campaign (BCC) scientists at the University of Southampton in the UK have come across a way of curbing breast cancer cells' craving for sugar.
Research has shown that cancer cells thrive on sugar from the blood. The cells process sugar as a fuel supply that encourages C-terminal binding proteins (CtBPs) to bind together. This process forms pairs of cells called "dimers," which enable the cancer cells to grow and multiply.
The researchers developed a variety of chemicals called cyclic peptide inhibitors, which can block CtBPs from forming. When tested on breast cancer cells, the most effective chemical for this process was found to be CP61.
The researchers say they are now developing CP61 to be used as a form of breast cancer treatment.
Dr. Jeremy Blaydes of the university's faculty of medicine says that although there have been major improvements in the treatment of breast cancer, chemotherapy-resistance eventually happens in around 20% of breast cancer cases. Chemotherapy-resistance shows when cancers that had previously responded to therapy suddenly begin to grow.
"To overcome this resistance, innovative treatments that use new approaches to stop cancer from growing are desperately needed.
Because this is an entirely new approach to treatment, the drugs we are developing could be effective against breast cancers that have become resistant to current chemotherapies."
Dr. Blaydes adds that this discovery of a potential treatment for breast cancer is made even more exciting because CtBPs are only active in cancer cells.
Therefore, blocking the "sweet-tooth" craving of the cancer cells should cause less damage to normal healthy cells and fewer side effects compared with existing treatments.
"This work is at an early stage in the laboratory, but it is really exciting as it has the potential to deliver a completely new kind of cancer drug, which could be available within 10 years."
Dr. Stuart Griffiths, director of research at Breast Cancer Compaign, says that for women whose breast cancer has become resistant to chemotherapy, this treatment could potentially offer a much needed lifeline. He adds:
"Every year, thousands of women still die and millions are affected by breast cancer, so we will continue to seek out world-class research, bringing the brightest minds together to share knowledge and produce better, quicker results."
Written by Honor Whiteman
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
A cyclic peptide inhibitor of C-terminal binding protein dimerization links metabolism with mitotic ﬁdelity in breast cancer cells, Chemical Science. 1 August 2013.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Whiteman, Honor. "Curbing breast cancer's craving for sugar." Medical News Today. MediLexicon, Intl., 3 Aug. 2013. Web.
21 Apr. 2014. <http://www.medicalnewstoday.com/articles/264318>
Whiteman, H. (2013, August 3). "Curbing breast cancer's craving for sugar." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/264318.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.